Why the study?
Does AR-C69931MX reduce reocclusion and improve myocardial tissue perfusion in a canine thrombosis model receiving thrombolytic therapy?
Does AR-C69931MX reduce reocclusion and improve myocardial tissue perfusion in a canine thrombosis model receiving thrombolytic therapy?
Adjunctive administration of the P2Y12 antagonist AR-C69931MX with t-PA reduces reocclusion and improves myocardial tissue perfusion in a canine thrombosis model.
Answers are grounded in this paper and cite their sources.
Supports adjunctive P2Y12 antagonism in thrombolysis models; leaves open translation to human reperfusion.
OBJECTIVE: Reperfusion therapy for myocardial infarction is limited by a significant reocclusion rate and less optimal myocardial tissue perfusion due to excessive platelet accumulation and recruitment at the sites of vascular injury. We assessed the influence of a selective P2Y(12)-receptor antagonist (AR-C69931MX), in conjunction with thrombolytic therapy, on the prevention of platelet aggregation and thrombus formation. METHODS AND RESULTS: A canine coronary electrolytic injury thrombosis model was used. Tissue-type plasminogen activator (t-PA; 1 mg/kg in phase I, 0.5 mg/kg in phase II in the AR-C69931MX group, and 1 mg/kg in the placebo group in phase I and II) was administered 30 minutes after thrombus formation; either saline or AR-C69931MX (4 micro g x kg(-1) x min(-1)) was given to all animals intravenously 10 minutes before t-PA administration for a total of 2 hours. All animals received heparin (80 U/kg) as an intravenous bolus followed by a continuous infusion of 17 U x kg(-1) x h(-1). Myocardial tissue perfusion was evaluated by use of the colored microsphere technique and real-time myocardial contrast echocardiography. The incidences of reocclusion and cyclic flow variation were significantly decreased in the AR-C69931MX group (P<0.05). Myocardial tissue flow with AR-C69931MX treatment improved significantly at 20 and 120 minutes after reflow, whereas tissue flow with placebo remained at a level similar to that during occlusion (P<0.05). CONCLUSIONS: The adjunctive administration of AR-C69931MX blocked ADP-mediated platelet aggregation and recruitment and prevented platelet-mediated thrombosis, resulting in prolongation of reperfusion time and a decrease in reocclusion and cyclic flow variations. Importantly, myocardial tissue perfusion was significantly improved in the P2Y(12) antagonist group.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: